Florida's Recreational Marijuana Measure Flames Out -- but There Is a Silver Lining

Source The Motley Fool

Marijuana measures on state ballots don't offer the same "wow" factor they once did. But every so often, a state that can deliver big-time cannabis sales puts a recreational pot measure up for vote. This election cycle, it was the long-awaited attempt to legalize personal-use marijuana in Florida.

Amendment 3 would allow adults 21 and over to purchase and possess up to 3 ounces of cannabis for personal use. It would also grant medical cannabis dispensaries the ability to cultivate, sell, and distribute recreational weed for personal use.

An up-close view of a flowering cannabis plant inside a large indoor cultivation farm.

Image source: Getty Images.

Florida's cannabis amendment is a buzzkill

The Sunshine State is the third largest cannabis market by sales in the U.S., behind only Michigan and California -- and this is only accounting for medical marijuana sales. Unfortunately, the buzz surrounding Amendment 3 flamed out on Election Day.

Despite support from Republican Party presidential nominee Donald Trump, just 55.9% of the roughly 10.6 million votes cast for Amendment 3 were in favor of its passage.

Because the Sunshine State's constitution needs to be amended to legalize adult-use weed, a 60% "yes" vote would have been necessary for it to pass. It's undoubtedly a disappointment for marijuana companies that have been steadily building their presence in Florida, including Trulieve Cannabis (OTC: TCNNF), Verano Holdings (OTC: VRNO.F), and AYR Wellness (OTC: AYRW.F).

But wait -- there's a silver lining

While the failure of Amendment 3 isn't what the Floridian majority had hoped for, there's still something of a silver lining for the likes of Trulieve, Verano, and AYR, which have enjoyed immense success by selling higher-margin medical marijuana.

Under Joe Biden's administration, the wheels have been put into motion to reschedule marijuana from a Schedule I to a Schedule III substance, under the Controlled Substances Act (CSA). The U.S. Drug Enforcement Administration will be holding a hearing before an administrative law judge that's set to begin in early December, and that may pave the way for an official rescheduling of cannabis under the next administration.

Even without the approval of recreational marijuana in Florida, the rescheduling of cannabis under the CSA would be a massive win for Trulieve, Verano, and AYR. Currently, internal revenue code Section 280E disallows companies that traffic federally controlled substances from taking normal tax deductions, outside of cost of goods sold. A potential move to Schedule III would remove this burden and immediately improve the profit potential for these companies.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

  • Amazon: if you invested $1,000 when we doubled down in 2010, you’d have $22,050!*
  • Apple: if you invested $1,000 when we doubled down in 2008, you’d have $41,999!*
  • Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $407,440!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

See 3 “Double Down” stocks »

*Stock Advisor returns as of November 4, 2024

Sean Williams has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Ayr Wellness and Trulieve Cannabis. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
EURUSD Long-term Forecast: Can ECB Hawks Overcome the Dollar Bullishness? As one of the most traded currency pair in the forex markets, the price of EURUSD affects many traders. Check out our EURUSD long-term forecast for more information.
Author  Mitrade
Mar 13, 2023
As one of the most traded currency pair in the forex markets, the price of EURUSD affects many traders. Check out our EURUSD long-term forecast for more information.
placeholder
Natural Gas sinks to pivotal level as China’s demand slumpsNatural Gas price (XNG/USD) edges lower and sinks to $2.56 on Monday, extending its losing streak for the fifth day in a row. The move comes on the back of China cutting its Liquified Natural Gas (LNG) imports after prices rose above $3.0 in June. It
Author  FXStreet
Jul 01, Mon
Natural Gas price (XNG/USD) edges lower and sinks to $2.56 on Monday, extending its losing streak for the fifth day in a row. The move comes on the back of China cutting its Liquified Natural Gas (LNG) imports after prices rose above $3.0 in June. It
placeholder
Gold price drops to one-week low, downside seems limited amid US political uncertaintyGold price (XAU/USD) attracts fresh sellers during the Asian session on Tuesday and drops to over a one-week low, around the $2,725-2,724 region, though the downside seems cushioned.
Author  FXStreet
Yesterday 06: 59
Gold price (XAU/USD) attracts fresh sellers during the Asian session on Tuesday and drops to over a one-week low, around the $2,725-2,724 region, though the downside seems cushioned.
placeholder
Novo Nordisk Q3 Earnings Preview: Investors to Focus on Wegovy SalesInsights– Novo Nordisk (NVO.US) is set to release its Q3 earnings before the market opens on Wednesday, November 6. Investors will focus on the latest supply-demand dynamics and market share of its
Author  Mitrade
Yesterday 09: 32
Insights– Novo Nordisk (NVO.US) is set to release its Q3 earnings before the market opens on Wednesday, November 6. Investors will focus on the latest supply-demand dynamics and market share of its
placeholder
Should Netflix Replace Tesla in the "Magnificent Seven"?There's a disruptive enterprise in a completely different industry that has done almost as well. Netflix (NASDAQ: NFLX) is up 1,300% in the last 10 years. Clearly, both businesses would have made investors a lot of money.
Author  The Motley Fool
21 hours ago
There's a disruptive enterprise in a completely different industry that has done almost as well. Netflix (NASDAQ: NFLX) is up 1,300% in the last 10 years. Clearly, both businesses would have made investors a lot of money.
goTop
quote